account_id none on file
legal_name Maravai Lifesciences Holdings, Inc.
ticker MRVI
cik 1823239
domain maravai.com
linkedin_company_url https://www.linkedin.com/company/maravai-lifesciences/
entry_point_account_id none on file
name Maravai LifeSciences Holdings Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 68 executives 3 family 0
why_nownone on file
callsnone on file
filings
of salaries, benefits and stock-based compensation expense for our employees in our commercial sales functions, marketing, executive, accounting and finance, legal and human resource functions as well as travel expenses, professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated costs, including facilities, information technology and amortization of intangibles.
filing / Aug 7, 2026 / receipt
Realignment Plan”) that included the termination of approximately 25 % of the Company’s workforce, a phased reduction of the Company’s facilities footprint, and other actions designed to significantly reduce operating costs and focus our resources on projects that we believe will deliver sustainable long-term growth, including improving our e-commerce presence.
filing / Aug 7, 2026 / receipt
We expect cost of revenue to remain below prior-year levels as a percentage of revenue as we continue to realize the benefits of our restructuring actions.
filing / Aug 7, 2026 / receipt
We expect our selling, general and administrative expenses to remain below prior-year levels as we continue to realize the benefits of our restructuring actions, while remaining relatively stable for the remainder of the fiscal year.
filing / Aug 7, 2026 / receipt
of salaries, benefits and stock-based compensation expense for our employees in our commercial sales functions, marketing, executive, accounting and finance, legal and human resource functions as well as travel expenses, professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated costs, including facilities, information technology and amortization of intangibles.
filing / May 8, 2026 / receipt
Realignment Plan”) that included the termination of approximately 25 % of the Company’s workforce, a phased reduction of the Company’s facilities footprint, and other actions designed to significantly reduce operating costs and focus our resources on projects that we believe will deliver sustainable long-term growth, including improving our e-commerce presence.
filing / May 8, 2026 / receipt
The reduction in force was substantially completed as of November 4, 2025, following the end of the sixty-day notification period required by the Worker Adjustment and Retraining Notification Act (the “WARN Act”).
filing / May 8, 2026 / receipt
The Company’s restructuring charges by segment and unallocated corporate costs, which are recorded as restructuring expenses on the condensed consolidated statements of operations, were as follows for the three months ended March 31, 2026 (in thousands):
filing / May 8, 2026 / receipt
>$65M cost removal exceeded target.
ir_statement / Sep 17, 2026 / receipt
Corporate Realignment Plan launched. Ultimately >$65M removed.
ir_statement / Sep 17, 2026 / receipt
Full C-suite restructured.
ir_statement / Sep 17, 2026 / receipt
Refers to restructuring costs (benefit) associated with the 2025 Corporate Realignment Plan.
ir_statement / Sep 17, 2026 / receipt
executives
| Bernd Brust | Chief Executive Officer | - | receipt |
| Rajesh Asarpota | Chief Financial Officer | - | receipt |
| Robert Andrew Eckert | director | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2025-06-25 | Chief Financial Officer, appointed | sec_8k |
| 2025-06-09 | Chief Executive Officer, appointed | sec_8k |
| 2024-12-05 | director, appointed | sec_8k |
mcp_package_hint
slug maravai-lifesciences-holdings-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$